The use of statins in optimising reduction of cardiovascular risk: Focus on fluvastatin

Alberto Corsini

doi:10.1111/j.1368-5031.2004.00154.x

The use of statins in optimising reduction of cardiovascular risk: Focus on fluvastatin

Alberto Corsini

IRCCS Multimedica

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with widely differing degrees of cardiovascular risk can derive benefit from effective lipid-lowering therapy with statins, including patients with normal or low cholesterol levels. Clinical trials with fluvastatin have shown that it is effective in patients across a broad spectrum of cardiovascular risk. The lipid-lowering effects of fluvastatin are smaller than some statins, but major clinical outcome studies have consistently demonstrated morbidity and mortality benefits with reductions of low-density lipoprotein cholesterol of

Original language	English
Pages (from-to)	494-503
Number of pages	10
Journal	International Journal of Clinical Practice
Volume	58
Issue number	5
DOIs	https://doi.org/10.1111/j.1368-5031.2004.00154.x
Publication status	Published - May 2004

Keywords

Adverse effects
Cardiovascular benefits
Drug interactions
HMG-CoA reductase inhibitors
Hypercholesterolaemia
Pleiotropic effects

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1111/j.1368-5031.2004.00154.x

Fingerprint Dive into the research topics of 'The use of statins in optimising reduction of cardiovascular risk: Focus on fluvastatin'. Together they form a unique fingerprint.

Cite this

@article{c796cfbc3cd7401b9e5301883826c035,

title = "The use of statins in optimising reduction of cardiovascular risk: Focus on fluvastatin",

abstract = "Patients with widely differing degrees of cardiovascular risk can derive benefit from effective lipid-lowering therapy with statins, including patients with normal or low cholesterol levels. Clinical trials with fluvastatin have shown that it is effective in patients across a broad spectrum of cardiovascular risk. The lipid-lowering effects of fluvastatin are smaller than some statins, but major clinical outcome studies have consistently demonstrated morbidity and mortality benefits with reductions of low-density lipoprotein cholesterol of ",

keywords = "Adverse effects, Cardiovascular benefits, Drug interactions, HMG-CoA reductase inhibitors, Hypercholesterolaemia, Pleiotropic effects",

author = "Alberto Corsini",

year = "2004",

month = may,

doi = "10.1111/j.1368-5031.2004.00154.x",

language = "English",

volume = "58",

pages = "494--503",

journal = "International Journal of Clinical Practice",

issn = "1368-5031",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - The use of statins in optimising reduction of cardiovascular risk

T2 - Focus on fluvastatin

AU - Corsini, Alberto

PY - 2004/5

Y1 - 2004/5

N2 - Patients with widely differing degrees of cardiovascular risk can derive benefit from effective lipid-lowering therapy with statins, including patients with normal or low cholesterol levels. Clinical trials with fluvastatin have shown that it is effective in patients across a broad spectrum of cardiovascular risk. The lipid-lowering effects of fluvastatin are smaller than some statins, but major clinical outcome studies have consistently demonstrated morbidity and mortality benefits with reductions of low-density lipoprotein cholesterol of

AB - Patients with widely differing degrees of cardiovascular risk can derive benefit from effective lipid-lowering therapy with statins, including patients with normal or low cholesterol levels. Clinical trials with fluvastatin have shown that it is effective in patients across a broad spectrum of cardiovascular risk. The lipid-lowering effects of fluvastatin are smaller than some statins, but major clinical outcome studies have consistently demonstrated morbidity and mortality benefits with reductions of low-density lipoprotein cholesterol of

KW - Adverse effects

KW - Cardiovascular benefits

KW - Drug interactions

KW - HMG-CoA reductase inhibitors

KW - Hypercholesterolaemia

KW - Pleiotropic effects

UR - http://www.scopus.com/inward/record.url?scp=2942699886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942699886&partnerID=8YFLogxK

U2 - 10.1111/j.1368-5031.2004.00154.x

DO - 10.1111/j.1368-5031.2004.00154.x

M3 - Article

C2 - 15206507

AN - SCOPUS:2942699886

VL - 58

SP - 494

EP - 503

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 5

ER -

The use of statins in optimising reduction of cardiovascular risk: Focus on fluvastatin

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this